Janno Roele’s Post

This week we've had Eyes On some of the competitive activities in BioPharma. Check out some of the M&A, New Clinical Data, Biosimilar growth and more. https://wix.to/rC6IQaW #newblogpost #PharmaCompetitiveIntel #BioPharmaNews #PharmaTell #EyesOnPharma

As the 10th anniversary of the first biosimilar approval in the United States approaches, understanding how the biosimilar environment has changed since 2015 will be key for providers, patients, payer organizations, and policymakers hoping to realize the benefits of biosimilars. My colleagues (Hanaa Siddiqi, Ben Diner, and Melissa Caplen) and I recently authored a white paper discussing the following on biosimilars in the United States: -Biosimilar landscape -Evolution of the barriers -Formulary coverage and uptake -How the #InflationReductionAct may impact the market

Do you want to know what impact the #IRA has had on Medicare Part D formularies for 2025? Look no further. My colleagues and I recently published an article outlining the key trends in formulary coverage based on a scan of the 2025 formulary landscape. One of the more interesting views is the positioning for Humira and the adalimumab biosimilars (below), where you see a divergence between the #PDP and #MAPD market, with #Humira maintaining access for >95% of members with MAPDs versus just over 50% of PDP members. It will be interesting to see how #biosimilar uptake plays out with these strategies. Knowing what happened is important, but knowing what is going to happen is even more important. We are already looking to 2026 and assessing what the drivers will be, including negotiated drugs, indication expansions, proposed new rules, and additional biosimilars and generics. Reach out if you want to find out how to best position yourself within your market. Check out our analysis here: https://lnkd.in/g6VC2kvR

We’re about to see another big year for the U.S. biosimilar market in 2025, when eight biosimilar alternatives to Stelara (ustekinumab) are expected to launch. This represents an opportunity to increase competition and reduce specialty costs. As we saw with Humira biosimilars, educating members and providers about the clinical efficacy and safety of these products will be crucial to help ensure a smooth transition to more affordable alternatives. Read more here: https://cvs.co/4eM2z1S

💡Did you know? 💡 Our Multiple Sclerosis Documentation System (MSDS) - AOK PLUS Linked Database is now available in the HMA-EMA Real-World Data (RWD) Catalogues: https://lnkd.in/ed9n6ZAZ This listing allows researchers, regulators, and pharmaceutical professionals to easily locate and utilise our MSDS database as a trusted source for real-world evidence in multiple sclerosis. The HMA-EMA Catalogues make it simple to find data that supports critical insights into the safety, effectiveness, and utilisation of treatments. Visit the HMA-EMA RWD Catalogues to see where we’re listed and learn more about how GIPAM supports data-driven decision-making in healthcare: https://lnkd.in/ekGYWM7i And if you're attending #ISPOREurope in Barcelona, stop by Booth 807 to learn more about our linked databases as well as our cutting-edge tools: EVIGATOR, ONCOCASE, and ANCHOR. #Healthcare #GIPAM #researchers

Interested to learn more about visual inspection in intravitreal injections? Ragunath Ananthavettivelu from ten23 health will speak about the challenges in the visual inspection of small volume parenterals, using the example of intravitreal products. Please reach out to me if you want to understand how ten23 health can support your needs in drug product development and sterile GMP fill-finish of intravitreal 👁️ products.

The nasal delivery market is set to increase to US$75.7B by 2030. some possible reasons for this could be an Increasing acceptance that the nasal route offers the potential for local, systemic and direct to brain delivery whilst avoiding first pass metabolism and Patient preference and the attractiveness of self administration make it an ideal alternative to injectable dosage forms. #nasal #nasalformulations #CDMO #RDD2024

Thoughts on this? >> EMA's CHMP recommends 10 new drugs as Pierre Fabre overactive bladder med wins approval >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #pharma #biotech #productmarketing

Recently, we had the opportunity to attend the DIA Global Annual Meeting, a premier event for the pharmaceutical and biotech sectors. With professionals from four different continents, #DIA2024 was the perfect venue to collaborate, advance ideas, and shape the landscape of clinical operations. Throughout the conference, one of the things we noticed was the significant emphasis on direct-to-patient (DTP) and direct-from-patient (DFP) shipping. Industry experts highlighted the increasing importance of these solutions for improving patient access to new products and clinical trials. It’s a shift that’s being driven by the demand for better #healthcare and the efficiency of patient-centric logistics. We also heard insights on everything from track and trace capabilities to public health and data monitoring. For more of our takeaways from DIA 2024, check out the full article here: https://lnkd.in/dTMknmk8

Thoughts on this? >> Arrowhead reports full Phase 2b data for lipid drug plozasiran, but Ionis is a step ahead: #ACC24 >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #healthcare #productmarketing #biotech